FOR THE HCP: I certify and warrant that all patient information supplied to Keryx Patient Plus and/or Keryx Biopharmaceuticals, Inc. affiliates has been obtained pursuant to an appropriate patient authorization allowing for the release, transfer, and use of such information by Keryx Biopharmaceuticals, Inc. in accordance with State and Federal law for verification and/or … Boston, Massachusetts 02210 (617) 466-3500 (Name and address of agent for service) We develop zerenex™ an oral, iron-based compound that has the capacity to bind to phosphate and forms non-absorbable … Password. Non-US country and region specific information is not available on this page. However, the … Keryx Biopharmaceuticals, Inc. (KERX): $3.36-0.07 (-2.04%) POWR Rating. December 13, 2018 07:00 AM Eastern Standard Time. ... Keryx Biopharmaceuticals Inc. ... Keryx posted wider than expected loss in the second quarter of 2017 but sales exceeded expectations. Drugs are a life-or-death business for Keryx Biopharmaceuticals. 2018-11-08: Keryx Biopharmaceuticals Announces Third Quarter 2018: 2018-08-08: Keryx Biopharmaceuticals Announces Second Quarter 2018: 2018-06-29: Keryx Biopharmaceuticals, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to Keryx Biopharmaceuticals, Inc.’s Registration Statement on Form S-8, filed on June 29, 2018) Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Address. This is the Keryx Biopharmaceuticals company profile. Username or Email Address. Keryx Biopharmaceuticals recognized for iron deficiency anemia treatment approved for early-stage chronic kidney disease patients New York, NY—April 3, 2018—Keryx Biopharmaceuticals has been selected to receive the 2018 Corporate Innovator Award from the National Kidney Foundation (NKF) at its 27th annual Spring Clinical Meetings in Austin, Texas. Katrin UHLIG, Senior Medical Director of Keryx Biopharmaceuticals, NY | Read 78 publications | Contact Katrin UHLIG We maintain a website on the Internet at www.keryx.com and our e-mail address is info@keryx.com. Keryx Biopharmaceuticals' physical mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. All other trademarks, service marks, and trade names referenced in this Annual Report on Form 10-K are the property of their respective owners. It supports investigator sponsored research conducted by independent researchers with Keryx’s established U.S. sales and marketing organization and its medical affairs team have built strong awareness within the nephrology community to address the needs of patients with CKD, and will drive the launch preparation and execution for vadadustat in the United States, subject to its * Keryx Biopharmaceuticals - additional medicare Part D plan sponsor has added auryxia to medicare Part D plan formularies, effective June 1, 2017 Oklahoma City, OK: A securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Keryx Biopharmaceuticals Inc, (NASDAQ: KERX). Keryx Biopharmaceuticals, Inc. operates as a commercial stage biopharmaceutical firm. Sign Up ... Just enter your email address below. If you purchased shares of Keryx Biopharmaceuticals from February 25, 2016 through August 1, 2016 and would like to join the action, please click "Join This Class Action" above. Glassdoor gives you an inside look at what it's like to work at Keryx Biopharmaceuticals, including salaries, reviews, office photos, and more. Patheon Manufacturing Services LLC of Greenville, North Carolina, a global provider of pharmaceutical manufacturing services, is now an FDA-approved drug product manufacturer of Auryxia (ferric citrate), Keryx … We are investigating Keryx Biopharmaceuticals, Inc ("Keryx" or the "Company") (NasdaqCM:KERX) relating to the sale of the Company to Akebia Therapeutics.(“Akebia”). Phone (617) 871-2098. All content is posted anonymously by employees working at Keryx Biopharmaceuticals. • Rev Up Your Portfolio with RPM International Address: One Marina Park Drive,12h Floor Boston, MA 02210 Tel: +1-617-466-3550 Fax: +1-617-466-3501 Website: www.keryx.com. Appendix B Intellectual Property Agreement with Yeda Research and Development Co., Ltd. AGREEMENT This Agreement, dated _____, 2001 (the "Effective Date"), by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), a Delaware corporation having an address at 5 Kiryat Mada, Jerusalem, Israel 91236, Yeda Research and Development Co. Ltd., an Israeli company having an address … Keryx Biopharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. KERYX BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its ... 531-5965. Under the terms of the agreement, Keryx shareholders are only anticipated to receive 0.37433 shares of Akebia for each share of Keryx common stock held. The companies are to form a new, fully integrated company focused … Kite Pharma Inc. (Address of Principal Executive Offices) (Zip Code) KERYX BIOPHARMACEUTICALS, INC. Company Description. Chief Executive Officer . Keryx Biopharmaceuticals is a biopharmaceutical company that is focused on the development and commercialization of medicines for chronic kidney diseases. Keryx Biopharmaceuticals Inc.KERX reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents. Component Grades. Correspondence address Keryx Biopharmaceuticals, Inc., One, Marina Park Drive, Boston, Massachusetts Ma 02210, United States . Most Popular Stories View All • 4,000 or Bust for S&P 500! Keryx Biopharmaceuticals is similar to Anika Therapeutics, Appneta, Redi Carpet, CJP, and Motus Trusted by Google, Microsoft, and most of the Fortune 500 to provide accurate contact information to their Sales and Business Development teams. Profile: Keryx Biopharmaceuticals, Inc. is focused on the acquisition and development of novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.Our products include zerenex™, KRX-0401, KRX-0501 and KRX-0701. Keryx Biopharmaceuticals offers Auryxia, a medicine that is able to lower the amount of phosphate in blood. See other locations. The biopharmaceutical company's listed phone number is 617-466-3500 and its investor relations email address is [email protected] The official website for Keryx Biopharmaceuticals is www.keryx… Keryx Biopharmaceuticals Inc. KERX | Keryx Biopharmaceuticals, Inc. | Video Chart for 04/25/12 by http://bluehorseshoestocks.com Keryx Biopharmaceuticals, Inc. One Marina Park Drive, 12 th Floor Boston, MA 02210 (617) 466-3500 (Name, address, including zip code, and telephone number, including area code, of … Keryx Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products for patients with renal disease. The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws. This Annual Report on Form 10-K contains trademarks and trade names of Keryx Biopharmaceuticals, Inc., ... Our telephone number is 617-466-3500, and our e-mail address is info@keryx.com. In terms of relative price strength - which takes into account the overall market trend - the Keryx Biopharmaceuticals Inc price has moved by -35.09% over the past year. Address: 333 Lakeside Drive, Foster City, CA 93404 Tel: +1 650 574 3000, 1 800 455 3235, 1 800 GILEAD-5 The U.S. Food and Drug Administration has approved Keryx Biopharmaceuticals' application for a second drug product contract manufacturer, the Boston-based company said Nov. 9. Today, Akebia Therapeutics and Keryx Biopharmaceuticals announced an all-stock merger. The company specializes in developing treatments for life-threatening ailments, such as cancer and kidney disease. Medications listed here may also be marketed under different names in different countries. Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company. Keryx Biopharmaceuticals, Inc. One Marina Park Drive, 12 th Floor . 245 1ST St. Cambridge , MA, 02142-1200 United States. Hyperphosphatemia Drugs Market 2021 Showcases Capable Growth After Covid-19 Pandemic with Top Manufacturers: Shire, Keryx Biopharmaceuticals, Sanofi AMENDED AND RESTATED 2013 INCENTIVE PLAN (Full title of the plan) Gregory P. Madison . This Annual Report on Form 10-K contains trademarks and trade names of Keryx Biopharmaceuticals, Inc., including our name and logo. Shares in Keryx Biopharmaceuticals Inc are currently trading at $3.36 and the price has moved by -24.78% over the past 365 days.